Predictive value of high sensitivity C-reactive protein in three-vessel disease patients with and without type 2 diabetes

Table 3 Association between hs-CRP and endpoints in TVD patients with and without diabetes

Patients with diabetes	Events (n%)	Model 1^a		Model 2^b		Model 3^c
Patients with diabetes	Events (n%)	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
All-cause death
Hs-CRP < 2 mg/L	24 (4.3)	Reference		Reference		Reference
Hs-CRP ≥ 2 mg/L	18 (3.8)	0.99 (0.54–1.84)	0.997	1.03 (0.55–1.92)	0.924	1.63 (0.58–4.58)	0.349
MACCE
Hs-CRP < 2 mg/L	183 (32.4)	Reference		Reference		Reference
Hs-CRP ≥ 2 mg/L	178 (37.4)	1.34 (1.09–1.65)	0.005	1.29 (1.05–1.60)	0.015	1.51 (1.09–2.10)	0.013

Patients without diabetes	Events (n%)	Model 1^a		Model 2^b		Model 3^c
Patients without diabetes	Events (n%)	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
All-cause death
Hs-CRP < 2 mg/L	14 (1.7)	Reference		Reference		Reference
Hs-CRP ≥ 2 mg/L	15 (1.7)	0.89 (0.42–1.85)	0.757	0.82 (0.38–1.74)	0.606	0.22 (0.05–0.93)	0.039
MACCE
Hs-CRP < 2 mg/L	219 (27.0)	Reference		Reference		Reference
Hs-CRP ≥ 2 mg/L	273 (31.0)	1.14 (0.95–1.36)	0.145	1.15 (0.96–1.38)	0.116	0.93 (0.71–1.22)	0.613

^aModel 1: covariates were adjusted for age and sex
^bModel 2: covariates were adjusted for age, sex, smoking and SBP
^cModel 3: covariates were adjusted for age, sex, smoking, SBP, HDL-C, LDL-C, ACS and revascularization in hospital
ACS acute coronary syndrome, CI confidence interval(s), HDL-C high-density lipoprotein cholesterol, HR hazard ratio, Hs-CRP high-sensitivity C-reactive protein, LDL-C low-density lipoprotein cholesterol, MACCE major adverse cardiac and cerebrovascular events, PCI percutaneous coronary intervention, SBP systolic blood pressure, TVD three-vessel disease

ISSN: 1475-2840